Literature DB >> 3747346

Phenacetin and papillary necrosis: independent risk factors for renal pelvic cancer.

M McCredie, J H Stewart, J J Carter, J Turner, J F Mahony.   

Abstract

A case-control study was undertaken to determine whether renal papillary necrosis (RPN) is an essential step in the genesis of analgesic-associated cancer of the renal pelvis (CaP). Kidneys of 66 patients (and 86 cases of renal parenchymal cancer (CaK), for comparison) were examined for evidence of RPN. Information concerning past consumption of phenacetin-containing analgesics (PhA) was obtained from all cases and 751 population controls by means of a questionnaire. Separately, RPN and regular consumption of PhA each conferred a relative risk for CaP of 3-1/2 to 7, while together they increased the risk some 20 times that for non-consumers without RPN. This suggests that each factor has independent, and when they coexist sequential, effects. The risk for CaK was doubled by regular PhA consumption but was not increased by RPN.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3747346     DOI: 10.1038/ki.1986.154

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  4 in total

1.  Risk factors for kidney cancer in New South Wales, Australia. II. Urologic disease, hypertension, obesity, and hormonal factors.

Authors:  M McCredie; J H Stewart
Journal:  Cancer Causes Control       Date:  1992-07       Impact factor: 2.506

Review 2.  Sickle cell disease and the kidney.

Authors:  Jon I Scheinman
Journal:  Nat Clin Pract Nephrol       Date:  2008-12-02

Review 3.  Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date.

Authors:  Jean-Pierre Cosyns
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 4.  Oncogenic mechanisms in renal insufficiency.

Authors:  Simona Ruxandra Volovat; Constantin Volovat; Ingrith Miron; Mehmet Kanbay; David Goldsmith; Cristian Lungulescu; Silvia Corina Badarau; Adrian Covic
Journal:  Clin Kidney J       Date:  2020-10-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.